Clinically, PAF–IL-6–TPO pathway is particularly relevant in conditions of reactive thrombocytosis, such as sepsis, autoimmune vasculopathies, and cancer-associated thrombosis, where excess platelet production exacerbates thrombotic risk [2,78]. This evidence concerns the gene IL6 and Venous thrombosis.